蓝帆医疗：子公司Lithonic 冠脉血管内冲击波治疗系统获得CE证书

Core Viewpoint - Bluesail Medical's subsidiary, Biosensors Interventional Technologies Pte. Ltd., has received EU CE certification for its Lithonic coronary intravascular shockwave treatment system, which is designed for pre-treatment of severely calcified stenosis, reducing the risk of complications such as vascular perforation and no-reflow [1] Company Summary - The certification signifies international recognition of the technology and strengthens the company's competitive advantage in the coronary field [1] - The expected positive impact on the company's operational development is highlighted [1] Industry Summary - The sales of medical devices are influenced by market conditions, indicating a need for cautious investment from stakeholders [1]